China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
17.96
+0.08 (0.45%)
Apr 29, 2026, 3:00 PM CST
SHA:600062 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 10,609 | 10,881 | 11,119 | 11,177 | 9,522 | 9,034 | Upgrade
|
| Other Revenue | 119.54 | 119.54 | 92.76 | 133.12 | 102.99 | 77.88 | Upgrade
|
| Revenue | 10,729 | 11,001 | 11,212 | 11,310 | 9,625 | 9,112 | Upgrade
|
| Revenue Growth (YoY) | -3.74% | -1.88% | -0.87% | 17.50% | 5.64% | 7.14% | Upgrade
|
| Cost of Revenue | 4,594 | 4,660 | 4,832 | 4,904 | 4,307 | 4,048 | Upgrade
|
| Gross Profit | 6,134 | 6,341 | 6,380 | 6,406 | 5,318 | 5,064 | Upgrade
|
| Selling, General & Admin | 3,877 | 4,006 | 4,127 | 3,937 | 3,478 | 3,502 | Upgrade
|
| Research & Development | 526.66 | 531.6 | 555.19 | 627.85 | 482.48 | 409.59 | Upgrade
|
| Other Operating Expenses | 76.16 | 88.57 | 75.98 | 106.24 | 119.35 | 115.75 | Upgrade
|
| Operating Expenses | 4,489 | 4,635 | 4,739 | 4,681 | 4,081 | 4,029 | Upgrade
|
| Operating Income | 1,646 | 1,706 | 1,641 | 1,725 | 1,237 | 1,034 | Upgrade
|
| Interest Expense | -33.58 | -33.58 | -15.36 | -15.4 | -10.62 | -11.62 | Upgrade
|
| Interest & Investment Income | 164.93 | 164.93 | 198.56 | 190.56 | 89.68 | 81.55 | Upgrade
|
| Earnings From Equity Investments | 33.28 | - | - | - | 16.23 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -3.53 | -3.53 | 9.19 | 6.6 | 18.06 | -4.97 | Upgrade
|
| Other Non Operating Income (Expenses) | -26.18 | 1.25 | 29.93 | 61.3 | 6.36 | 0.26 | Upgrade
|
| EBT Excluding Unusual Items | 1,781 | 1,836 | 1,863 | 1,968 | 1,357 | 1,099 | Upgrade
|
| Impairment of Goodwill | - | - | -29.41 | -28.9 | - | -56.68 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.29 | 1.83 | -1.64 | 13.7 | 5.99 | 35.36 | Upgrade
|
| Gain (Loss) on Sale of Assets | -8.55 | -10.1 | 46.84 | 0.18 | -2.27 | 1.03 | Upgrade
|
| Asset Writedown | -25.96 | -22.76 | -59.17 | -57.52 | -8.43 | -0.54 | Upgrade
|
| Other Unusual Items | 106.25 | 106.25 | 46.61 | 40.85 | 82.76 | 42.65 | Upgrade
|
| Pretax Income | 1,856 | 1,911 | 1,867 | 1,937 | 1,435 | 1,121 | Upgrade
|
| Income Tax Expense | 193.68 | 227.52 | 215.94 | 272.71 | 201.27 | 149.06 | Upgrade
|
| Earnings From Continuing Operations | 1,662 | 1,683 | 1,651 | 1,664 | 1,234 | 972.13 | Upgrade
|
| Minority Interest in Earnings | -36.72 | -36.27 | -23.02 | 6.29 | -53.59 | -36.45 | Upgrade
|
| Net Income | 1,625 | 1,647 | 1,628 | 1,670 | 1,180 | 935.69 | Upgrade
|
| Net Income to Common | 1,625 | 1,647 | 1,628 | 1,670 | 1,180 | 935.69 | Upgrade
|
| Net Income Growth | 0.24% | 1.18% | -2.55% | 41.55% | 26.12% | -6.91% | Upgrade
|
| Shares Outstanding (Basic) | 1,034 | 1,033 | 1,028 | 1,024 | 1,036 | 1,043 | Upgrade
|
| Shares Outstanding (Diluted) | 1,036 | 1,034 | 1,028 | 1,024 | 1,036 | 1,043 | Upgrade
|
| Shares Change (YoY) | 0.68% | 0.61% | 0.33% | -1.07% | -0.74% | - | Upgrade
|
| EPS (Basic) | 1.57 | 1.59 | 1.58 | 1.63 | 1.14 | 0.90 | Upgrade
|
| EPS (Diluted) | 1.57 | 1.59 | 1.58 | 1.63 | 1.14 | 0.90 | Upgrade
|
| EPS Growth | -0.43% | 0.57% | -2.87% | 43.09% | 27.06% | -6.91% | Upgrade
|
| Free Cash Flow | 741.45 | 869.88 | 1,188 | 1,245 | 889.57 | 849.25 | Upgrade
|
| Free Cash Flow Per Share | 0.72 | 0.84 | 1.16 | 1.22 | 0.86 | 0.81 | Upgrade
|
| Dividend Per Share | 0.479 | 0.479 | 0.471 | 0.257 | 0.578 | 0.480 | Upgrade
|
| Dividend Growth | 1.70% | 1.70% | 83.27% | -55.54% | 20.42% | 65.52% | Upgrade
|
| Gross Margin | 57.18% | 57.64% | 56.91% | 56.64% | 55.25% | 55.57% | Upgrade
|
| Operating Margin | 15.34% | 15.51% | 14.64% | 15.26% | 12.85% | 11.35% | Upgrade
|
| Profit Margin | 15.15% | 14.97% | 14.52% | 14.77% | 12.26% | 10.27% | Upgrade
|
| Free Cash Flow Margin | 6.91% | 7.91% | 10.59% | 11.01% | 9.24% | 9.32% | Upgrade
|
| EBITDA | 2,406 | 2,460 | 2,370 | 2,390 | 1,778 | 1,482 | Upgrade
|
| EBITDA Margin | 22.42% | 22.36% | 21.14% | 21.13% | 18.47% | 16.26% | Upgrade
|
| D&A For EBITDA | 760.03 | 753.81 | 728.93 | 664.52 | 540.36 | 447.4 | Upgrade
|
| EBIT | 1,646 | 1,706 | 1,641 | 1,725 | 1,237 | 1,034 | Upgrade
|
| EBIT Margin | 15.34% | 15.51% | 14.64% | 15.26% | 12.85% | 11.35% | Upgrade
|
| Effective Tax Rate | 10.44% | 11.91% | 11.57% | 14.08% | 14.03% | 13.30% | Upgrade
|
| Revenue as Reported | 11,001 | 11,001 | 11,212 | 11,310 | 9,625 | 9,112 | Upgrade
|
| Advertising Expenses | - | 79.39 | 85.96 | 35.82 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.